Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Analysts

Key Points

• Aclaris Therapeutics has received an average rating of "Buy" from nine brokerages, with eight analysts recommending buying and one assigning a strong buy.
• The average 12-month price target for Aclaris Therapeutics shares is $8.71, reflecting differing price objectives from various analysts, with the highest set at $16.00.
• Aclaris Therapeutics reported earnings of ($0.13) per share for the last quarter, meeting consensus estimates, with revenues of $1.78 million exceeding expectations of $1.34 million.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine research firms that are covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $8.7143.

ACRS has been the subject of a number of analyst reports. HC Wainwright reissued a "buy" rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research note on Wednesday, June 25th. Scotiabank lowered their target price on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating for the company in a research note on Friday, May 9th. Piper Sandler initiated coverage on shares of Aclaris Therapeutics in a research note on Thursday, July 10th. They set an "overweight" rating and a $6.00 target price for the company. Finally, Wedbush reissued an "outperform" rating and set a $8.00 target price on shares of Aclaris Therapeutics in a research note on Monday, June 23rd.

Hedge Funds Weigh In On Aclaris Therapeutics

Hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC raised its holdings in shares of Aclaris Therapeutics by 11.9% during the second quarter. Squarepoint Ops LLC now owns 390,583 shares of the biotechnology company's stock valued at $555,000 after purchasing an additional 41,666 shares during the period. Bridgeway Capital Management LLC raised its holdings in shares of Aclaris Therapeutics by 53.5% during the second quarter. Bridgeway Capital Management LLC now owns 443,319 shares of the biotechnology company's stock valued at $630,000 after purchasing an additional 154,600 shares during the period. Raymond James Financial Inc. raised its holdings in shares of Aclaris Therapeutics by 10.5% during the second quarter. Raymond James Financial Inc. now owns 277,259 shares of the biotechnology company's stock valued at $394,000 after purchasing an additional 26,454 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Aclaris Therapeutics during the second quarter valued at about $70,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Aclaris Therapeutics during the second quarter valued at about $48,000. Institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Stock Up 4.9%

Shares of ACRS stock traded up $0.09 during trading hours on Tuesday, hitting $1.93. 831,137 shares of the company's stock traded hands, compared to its average volume of 726,303. The stock's 50 day simple moving average is $1.62 and its 200 day simple moving average is $1.55. The stock has a market cap of $209.08 million, a PE ratio of -1.41 and a beta of 0.27. Aclaris Therapeutics has a 12 month low of $1.05 and a 12 month high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). The firm had revenue of $1.78 million during the quarter, compared to the consensus estimate of $1.34 million. Aclaris Therapeutics had a negative net margin of 802.03% and a negative return on equity of 34.01%. As a group, equities research analysts expect that Aclaris Therapeutics will post -0.82 EPS for the current fiscal year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.